Showing 2521-2530 of 3315 results for "".
- OHSU Researchers Discover Link Between Proteins in Tears, Pain After Eye Surgeryhttps://modernod.com/news/ohsu-researchers-discover-link-between-proteins-in-tears-pain-after-eye-surgery/2482376/Researchers at Oregon Health & Science University (OHSU) have discovered a connection between levels of certain proteins found in patients’ tears and persistent pain months after refractive surgery. The team hopes their findings, which were
- Johnson & Johnson Invests in Refractive Technology Start-Up TECLenshttps://modernod.com/news/johnson-johnson-invests-in-refractive-technology-start-up-teclens/2482372/Johnson & Johnson closed a transaction to co-lead the Series A funding of TECLens, a start-up developing a nonincisional refractive correction procedure that leverages corneal cross-linking (CXL) to reshape the cornea. Financial terms of the deal were not disclo
- Mount Sinai Ophthalmologists Present New Research at ASRShttps://modernod.com/news/mount-sinai-ophthalmologists-present-new-research-at-asrs/2482355/Ophthalmologists from New York Eye and Ear Infirmary of Mount Sinai in New York City have prepared the following research for the ASRS annual meeting in Stockholm, Sweden, July 17-20. FOUNDERS AWARD WINNER LECTURE Jammi
- iOR Partners Appoints Lance J. Kugler, MD, to the Role of Strategic Advisory Board Chairmanhttps://modernod.com/news/ior-partners-appoints-lance-j-kugler-md-to-the-role-of-strategic-advisory-board-chairman/2482351/Ophthalmic office-based surgery provider IOR Partners announced that Lance J. Kugler, MD, has been named Chairman of the Strategic Advisory Board. Dr. Kugler opened one of the first OBS suites in 2017 and published a study on the safety of office-based lens surgery in The
- Beacon Therapeutics Raises Funds to Advance Development of Its Ophthalmic Gene Therapieshttps://modernod.com/news/beacon-therapeutics-raises-funds-to-advance-development-of-its-ophthalmic-gene-therapies/2482341/Beacon Therapeutics announced it has raised $170 million in Series B funding, which will be used to support the continued clinical development of Beacon’s lead asset, AGTC-501, for X-linked retinitis pigmentosa (XLRP; laruparetigene zovaparvovec) and generate phase 1/2 clinical trial d
- NEI Funded Study Reveals Neural Mechanism of Encoding Familiar Faceshttps://modernod.com/news/nei-funded-study-reveals-neural-mechanism-of-encoding-familiar-faces/2482335/National Eye Institute funded research at University of Tsukuba demonstrated that faces of familiar individuals with whom one has frequent social interactions with are learned in the basal ganglia region through the same neural mechanisms that recognize the value of objects.
- Rayner Closes Recruitment for IDE for RayOne EMV Toric IOLshttps://modernod.com/news/rayner-closes-recruitment-for-ide-for-rayone-emv-toric-iols/2482332/Rayner announced that it has closed recruitment in the investigational device exemption (IDE) study for its EMV Toric IOL in the US. The study will ultimately enable the introduction of the RayOne EMV Toric lens for use in the US. Developed in collaboration with Professor
- Beacon Therapeutics Treats First Patient in VISTA Trial of AGTC-501 for XLRPhttps://modernod.com/news/beacon-therapeutics-treats-first-patient-in-vista-registrational-trial-for-agtc-501/2482319/Beacon Therapeutics announced the treatment of the first patient in its registrational VISTA clinical trial with its lead asset, AGTC-501 (laruparetigene zovaparvovec). VISTA is a global randomized, controlled, masked, multicenter pivotal study evaluating the efficacy, safety, and
- Nidek Receives CE Mark Approval for Preloaded IOL Injection Systemhttps://modernod.com/news/nidek-receives-ce-mark-approval-for-preloaded-iol-injection-system/2482315/Nidek has received CE Mark for the NP-1/NP-1C Preloaded IOL Injection System, a fully preloaded injection system with an aspheric hydrophobic soft acrylic lens designed for smoother, safer, and secure IOL implantation. The NP-1/NP-1C injector is developed for smooth, controlle
- Geoff Tabin, MD, Co-Founder of Global NGO HCP Cureblindness, Steps Into New Rolehttps://modernod.com/news/geoff-tabin-md-co-founder-of-global-ngo-hcp-cureblindness-steps-into-new-role/2482314/Effective immediately, Geoff Tabin, MD, will step down as Board Chair of the global nonprofit HCP Cureblindness (Himalayan Cataract Project), but will maintain an active role on the Board as Medical Director. Long-time HCP volunteer and Board Member, Matt Oliva, MD, will lead HCP into its excitin